


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (previously presented) A purified compound of formula 1:

Formula 1



and pharmaceutically acceptable salts, prodrugs, tautomers, and solvates, thereof.

2-15. (canceled)

16. (new) A compound according to claim 1, wherein the compound is a compound of formula 1 and pharmaceutically acceptable salts thereof.

17. (new) A compound according to claim 1, wherein the compound is a prodrug, tautomer, or solvate of a compound of formula 1.

18. (new) A compound according to claim 1, wherein the compound is 4(S)-MeHex-D-Val-L-Thr-L-Val-D-Val-D-Pro-L-Orn-D-*allo-Ile-cyclo*(D-*allo*-Thr-D-*allo*-Ile-D-Val-L-Phe-Z-Dhb-L-Val), and pharmaceutically acceptable salts, prodrugs, tautomers, and solvates, thereof.

19. (new) A compound according to claim 18, wherein the compound is 4(S)-MeHex-D-Val-L-Thr-L-Val-D-Val-D-Pro-L-Orn-D-*allo-Ile-cyclo*(D-*allo*-Thr-D-*allo*-Ile-D-Val-L-Phe-Z-Dhb-L-Val), and pharmaceutically acceptable salts thereof.

20. (new) A compound according to claim 18, wherein the compound is a prodrug, tautomer, or solvate of 4(S)-MeHex-D-Val-L-Thr-L-Val-D-Val-D-Pro-L-Orn-D-*allo-Ile-cyclo*(D-*allo*-Thr-D-*allo*-Ile-D-Val-L-Phe-Z-Dhb-L-Val).

21. (new) A pharmaceutical composition comprising a purified compound according to any one of claims 1, 16, 17, 18, 19, and 20 and a pharmaceutically acceptable carrier, vehicle or diluent.

22. (new) A kit comprising separate containers containing a pharmaceutical composition comprising a compound according to any one of claims 1, 16, 17, 18, 19, and 20 and a reconstituting agent.

23. (new) A method of preparing a compound according to any one of claims 1, 16, 17, 18, 19, and 20 comprising:

converting 4-MeHex-D-Val-L-Thr(tBu)-L-Val-D-Val-D-Pro-L-Orn(Boc)-D-*allo*-Ile-D-*allo*-Thr(L-Val-Z-Dhb-L-Phe-H)-D-*allo*-Ile-D-Val-OH  
to 4-MeHex-D-Val-L-Thr-L-Val-D-Val-D-Pro-L-Orn-D-*allo*-Ile-*cyclo*(D-*allo*-Thr-D-*allo*-Ile-D-Val-L-Phe-Z-Dhb-L-Val).

24. (previously presented) A method for preparing a compound according to any one of claims 1, 16, and 17 comprising:

providing 4-methyl hexanoic acid as a starting material in a process for preparing the compound according to any one of claims 1, 16, and 17.

25. (previously presented) A method for preparing a compound according to any one of claims 18-20 comprising:

providing (4S)-methyl hexanoic acid as a starting material in a process for preparing the compound according to any one of claims 18-20.

26. (new) A method of treating a mammal having cancer comprising:

administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1, 16, 17, 18, 19, and 20 .

27. (new) The method according to claim 26, wherein the mammal is a human.

28. (new) The method according to claim 26, wherein the cancer is a refractory cancer.

29. (new) A method of according to claim 26, wherein the cancer is a type of cancer for which the administered compound is more efficacious than 5-methyl hexanoic kahalalide F.

30. (new) The method according to claim 26, wherein the cancer is selected from prostate cancer, breast cancer, hepatocellular carcinoma, melanoma, colorectal cancer, renal cancer, ovarian cancer, lung cancer, leukemia, epithelial cancer, pancreatic cancer, and tumors that overexpress the Her2/neu oncogene.

31. (new) The method according to claim 26, wherein the cancer is selected from hepatocellular carcinoma, human liver adenocarcinoma, breast cancer, and prostate cancer.

32. (new) A method of manufacturing a medicament for the treatment of a viral infection or fungal infection comprising:

combining a compound according to any one of claims 1, 16, 17, 18, 19, and 20 with a pharmaceutically acceptable carrier, vehicle or diluent.

33. (new) A method of treating a mammal affected by a viral infection or a fungal infection comprising:

administering to the affected mammal a therapeutically effective amount of a compound according to any one of claims 1, 16, 17, 18, 19, and 20.